MAPK3 and ovarian carcinoma: By integrating network pharmacology, molecular docking, and molecular dynamics simulations with in vitro validation in ovarian cancer cells and TAMs, we aimed to delineate the dual modulatory actions of these marine secondary metabolites on the IL-17RA/Act1 and ERK1/2 pathways.